Abstract
Background
We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II–III breast cancer to evaluate correlations with primary tumor biology.
Methods
CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores.
Results
CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets.
Conclusion
It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
Similar content being viewed by others
REFERENCES
Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–695.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791.
Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688–695.
Rack B, Schindlbeck C, Juckstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5): pii: dju066.
Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18(20):5701–5710.
Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging: predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12(21):6403–6409.
Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153–5159.
Lang JE, Scott JH, Wolf DM, et al. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1):121–31.
Boral D, Vishnoi M, Liu HN, et al. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017;8(1):196.
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–584.
Zheng Y, Miyamoto DT, Wittner BS, et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017;8:14344.
Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013;64(2):114–8.
Lang JE, Magbanua MJ, Scott JH, et al. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genom. 2009;10:326.
Ring A, Mineyev N, Zhu W, et al. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget. 2015;6(42):44623–44634.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180–1184.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–325.
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167.
Gendoo DM, Ratanasirigulchai N, Schroder MS, et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32(7):1097–1099.
Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. http://www.bioinformatics.babraham.ac.uk/projects/fastqc. Accessed 15 Oct 2017
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–2120.
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.
Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002;30(1):42–46.
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012;2(5):401–404.
Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PloS One. 2012;7(5):e33788.
Gulbahce N, Magbanua MJM, Chin R, et al. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer research. 2017;77(16):4530–4541.
Porras TB, Kaur P, Ring A, Schechter N, Lang JE. Challenges in using liquid biopsies for gene expression profiling. Oncotarget. 2018;9(6):7036–7053.
Fukuda T, Shirane A, Wada-Hiraike O, et al. HAND2-mediated proteolysis negatively regulates the function of estrogen receptor alpha. Mol Med Rep. 2015;12(4):5538–5544.
Saitoh T, Katoh M. Molecular cloning and characterization of human WNT8A. Int J Oncol. 2001;19(1):123–127.
Nakanishi Y, Walter K, Spoerke JM, et al. Activating Mutations in PIK3CB Confer Resistance to PI3 K Inhibition and Define a Novel Oncogenic Role for p110beta. Cancer Res. 2016;76(5):1193–1203.
Elebro K, Borgquist S, Rosendahl AH, et al. High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients-results from a population-based breast cancer cohort. Clin Cancer Res. 2017;23(3):766–777.
Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9(9):1773–1782.
Kalinich M, Bhan I, Kwan TT, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017;114(5):1123–1128.
Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351–1356.
Acknowledgement
This project was supported by a Society of Surgical Oncology Clinical Investigator Award, a California Breast Cancer Research Program IDEA award, and a STOP Cancer Marni Levine Memorial Seed Grant (JL). The project was also supported in part by grant UL1TR001855 from the National Center for Advancing Translational Science (NCATS) and grant P30CA014089 from the National Cancer Institute of the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Magnetic cell separators were kindly made by the laboratory of Maciej Zborowski (Cleveland Clinic) based on the design provided by BD Biosciences.
Author information
Authors and Affiliations
Corresponding author
Additional information
Julie E. Lang and Alexander Ring served as co-first authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ELECTRONIC SUPPLEMENTARY Fig.
1 (a–d) Differential gene expression in CTCs based on hormone receptor expression in primary tumors. Heatmaps showing unsupervised hierarchical clustering of individual samples (CTCs or PTs) and volcano plots showing grouped (n = 16 CTCs and n = 12 PTs for a–c, n = 4 CTCs and PTs each for d) differential gene expression (p < 0.05) for: (a) TN samples vs. others (ER-positive or HER2-positive) [n = 512]; (b) ER-positive vs. others (HER2-positive or TNBC) [n = 115 genes]; (c) HER2-positive vs. others (ER-positive or TNBC) [n = 245 genes]; (d) pCR vs. no pCR (n = 65 genes) [color legend: maroon indicates TNBC, orange indicates ER-positive samples, teal indicates HER2-positive samples, green indicates pCR yes, gray indicates remaining samples in each comparison] (TIFF 2881 kb)
ELECTRONIC SUPPLEMENTARY Fig.
2 xCell gene signature-based classification of sample cellular composition. The cell type probability for each sample is shown in heatmap format. A score was calculated using the xCell script based on RNA-seq normalized gene expression (logRPKM + 1) in each sample (CTCs, PTs and PB) [color coding: blue indicates high score = high probability, white indicates low score = low probability] (TIFF 2702 kb)
ELECTRONIC SUPPLEMENTARY Fig.
3 NanoString results for ER (ESR1), PR (PGR), HER2 (ERBB2), and Ki67 (MKI67). A heatmap shows results for n = 13 FFPE tumors subjected to NanoString assays to characterize their biomarker profiles (PDF 113 kb)
Rights and permissions
About this article
Cite this article
Lang, J.E., Ring, A., Porras, T. et al. RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer. Ann Surg Oncol 25, 2261–2270 (2018). https://doi.org/10.1245/s10434-018-6540-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-018-6540-4